on ABL DIAGNOSTICS (EPA:ABLD)
ABL Diagnostics: New analysis published by All Invest Securities
On October 8, 2026, ABL Diagnostics announced the publication of a flash note by analyst Jean-Pierre Loza of All Invest Securities. This report, which assesses ABL Diagnostics, maintains the buy recommendation with a target price of €8.7 per share, forecasting continued growth beyond 2026.
The company, specializing in molecular diagnostic solutions, is diversifying through the integration of TEXCELL's activities, thereby expanding its expertise in virology and biopharmaceuticals. This strategy strengthens its presence in the life sciences sector.
The analysis remains accessible to professional investors in accordance with the MiFID II directive. Further details are available in the ABL Diagnostics investor relations section.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABL DIAGNOSTICS news